GDP for wholesalers regulates quality, storage, transport, CAPA and traceability through a system aligned with current CInMED and EU requirements.
Request an initial assessment
GDP for wholesalers regulates how the company maintains the quality and integrity of medicines from the approved supplier to the customer. ConsultHQ helps wholesalers in Montenegro to establish or improve the GDP system, adapt documentation to current CInMED and EU requirements and prepare the organization for regulatory verification.
A wholesaler can have a modern warehouse and good logistics, but still have serious GDP gaps.
The problem often arises between processes. Temperature monitoring exists, but the deviation has no quality investigation. The supplier is entered into the system, but the qualification is not sufficiently documented.
Or CAPA only exists in response to an inspection finding.
GDP should connect these activities into one controlled quality system.
The Law on Medicines (Official Gazette Nos. 14/26 and 94/26), particularly Articles 116–119, requires wholesalers to operate within their authorisation and GDP guidelines, employ a pharmacy-qualified responsible person full time and keep that person continuously available, and maintain a quality system defining responsibilities, procedures and risk controls. We review supplier and customer authorisations, safeguards against falsified medicines and traceability. Distribution records must remain accessible to CInMED for five years, and an emergency recall plan must work in practice.
The current Law on Medicines in Montenegro is currently kept as the "Official Gazette of Montenegro" 14/26 and 94/26. CInMED states that the new framework applies to procedures initiated from February 17, 2026. The amendments from July 2026 were additionally adopted in order to harmonize with the requirements of the European Commission and more precisely apply the law. (CInMED: Law on Medicines)
For humanitarian medicines, the European basis for Good Distribution Practices is still the Guidelines of the European Commission 2013/C 343/01. The European Commission still lists them as valid GDP guidelines for medicinal products for human use. (health.ec.europa.eu)
The EU GDP framework is based on Directive 2001/83/EC and sets requirements by which wholesalers preserve product quality and the integrity of the legal distribution chain. (EU GDP guidelines)
On July 22, 2026, CInMED published the current Good Practice Guidelines in the distribution of medicines for human use, and in August, standardized GDP and inspection documents aligned with the European regulatory system. (CInMED: good practice guidelines)
For ConsultHQ, this means one thing: we do not base the GDP project on old documentation or templates, but on the currently valid framework.
CInMED issues a license for wholesale distribution of medicinal products for human use.
The institute states that the permit, except for the sale of drugs containing drugs, is issued for an indefinite period. At the same time, the license holder must act according to GDP guidelines. (CInMED: good practice guidelines)
The GDP certificate is a special proof of the application of the guidelines.
CInMED issues it after verifying the fulfillment of the conditions, before the start of wholesale trade and at the request of the wholesaler, for a period of up to five years from the verification. (CInMED: wholesale requirements and forms)
ConsultHQ does not issue a GDP certificate.
Our job is to prepare the system, documentation and team so that they can prove compliance before CInMED.
For a company establishing a new operation, GDP implementation in Montenegro starts with clear responsibilities, processes and documentation. The scope of engagement depends on whether the company is just establishing wholesale, is already operating or is preparing for a new GDP check.
The project may include:
We do not introduce every possible GDP document.
First, we determine what processes wholesale actually has and where there is regulatory risk.
An existing wholesale business usually does not need a completely new system.
It may already have well-organized storage and monitoring, but the SOP procedures have not been updated according to the 2026 changes.
With another company, the documentation may look neat, while CAPA, change control or contracted transport control remain weak.
Through gap analysis, we review documentation and practice together.
The result should show:
Thus, resources are directed to real risks.
GDP is not the documentation of one department.
Procurement affects suppliers. The warehouse controls the physical product and its status.
Logistics manages transportation.
The responsible person must have sufficient information and authority to make a decision when there is a possible impact on the quality of medicines.
During implementation, we therefore review the connections between functions.
We clearly define responsibility where today there is room for different interpretation.
This reduces situations where a serious GDP event is left between two departments.
A generic GDP procedure often looks good until compared to the real process.
If the SOP describes steps that employees do not implement, the document becomes a regulatory risk instead of protection.
That's why we first follow the actual product flow.
From approved supplier and receiving, through warehouse and product status, to issuing and shipping.
Only after that we adjust the procedures.
The documentation should answer the employee's real question: what is my responsibility and what do I do when the process deviates?
The GDP system cannot rely on formal appointment without operational influence.
The responsible person should receive relevant information and participate in processes that may affect product quality.
During the gap analysis, we also review the organizational position of this function.
Processes such as:
If the responsible person finds out about the problem only after the decision has already been made, the system should be additionally arranged.
EU GDP guidelines play an important role in protecting the legal distribution chain and preventing the entry of counterfeit medicines. (EU GDP guidelines)
That's why, during implementation, we review how the wholesaler approves and tracks suppliers and customers.
The goal is not to create a large database for the sake of form.
It is necessary that the firm can prove that the partner has been verified according to the criteria relevant to GDP and that changes in his status are controlled.
Such a system reduces the risk of distribution outside the appropriate regulatory chain.
Temperature monitoring is important, but the logger itself is not a GDP system.
Space qualification, mapping, monitoring, calibration, alarms and deviations need to work together.
During the engagement, we check whether the existing system provides sufficiently reliable evidence of the storage conditions.
If there is a gap, we determine which activities need to be supplemented.
We do not turn a page or project into a universal technical instruction for sensor positioning.
The solution must correspond to the specific warehouse and product risk.
Hiring a transporter does not remove the need for the wholesaler to control the contracted GDP activity. That control includes GDP requirements for transport and storage, including activities assigned to external providers.
The EU GDP guidelines regulate outsourced activities, transport and responsibilities between the client and the executor. (EU GDP guidelines)
During the project we therefore review:
Products with a controlled temperature regime require special attention.
That's where proof must accompany risk.
In June 2026, CInMED published a special instruction for the submission of the CAPA plan after the GDP inspection and the harmonized CAPA form. The Institute expressly instructs wholesalers to use the prescribed model after the GDP inspection. (CInMED: CAPA instructions)
That is why we treat CAPA as one of the central processes of the GDP system.
We review whether the company:
Changing the procedure is not always a corrective measure.
If the problem comes from equipment, organization or competence, the solution should target the root cause.
A new cold room, WMS, conveyor or storage location changes the controlled system.
That's why we review how the company manages change.
The goal is to assess their impact before full implementation.
The change may require additional qualification, modification of SOP, training of employees or updating of regulatory documentation.
Such an operational improvement does not create a new GDP non-compliance.
When there is a problem with a particular series, the speed of data access becomes important.
The GDP system must therefore connect the warehouse, the customer and the relevant product data.
During the implementation, we review whether the wholesaler can reliably reconstruct the movement of the relevant product.
When returning, we check whether there are clear responsibilities to assess the further status.
In the event of a recall, the system should enable rapid identification of affected customers and inventory.
Here, the procedure is not sufficient if the data is not available.
During August 2026, CInMED published a number of standardized documents, including the GDP certificate for drugs for human use, the GDP inspection report, the license for the wholesale distribution of drugs, and the declaration of non-compliance with the GDP guidelines. (CInMED: good practice guidelines)
Current application forms are also available on the website of the Institute for Wholesale Trade.
The instructions and application for a wholesale license have been updated September 15, 2026, while the request for the GDP certificate was also published in the current version on September 15, 2026 (CInMED: wholesale requirements and forms)
That is why in the project we also check the versions of external regulatory documents.
The old form from the local computer is not automatically the current form.
The self-inspection should show how the system really works.
We don't just do it through a checklist.
We can track a single actual shipment from an approved supplier, through receipt and storage, to delivery to the customer.
Along the way, it becomes visible where documentation and practice differ.
The findings then feed into corrective actions.
This gives the wholesaler time to fix the problem before a regulatory inspection.
Procurement, warehouse and QA do not do the same job.
That is why GDP training should not be the same for everyone.
The warehouse needs a clear understanding of product status, storage conditions and deviations relevant to their work.
Procurement needs to understand supplier qualification.
Logistics needs to understand GDP transport requirements.
Responsible person and quality need a bigger picture of the system.
That's why we associate training with the function, not just with the name of the standard.
The result of the project should be a system that employees can continue to use.
Depending on the scope of the engagement, the client receives:
It is a functional regulatory system.
Not just a set of GDP documents.
A company can have hundreds of pages of SOP procedures and still have a weak system.
This happens when documentation exists separately from day-to-day operations.
Then records are arranged before inspection, employees do not understand their own responsibilities, and deviations are closed without real analysis.
Our approach is reversed.
We incorporate GDP requirements into the flows that wholesalers use on a daily basis.
Thus, the inspection checks the existing system.
Not the system that was activated a week earlier.
If the company already has a GDP system, we first review its currentness.
Changes to the 2026 Medicines Act, CInMED guidelines from July and regulatory forms from August and September do not automatically mean that every SOP needs to be rewritten. (CInMED: good practice guidelines)
It is necessary to determine their actual impact.
Some procedures may remain.
Others will require targeted modification.
Such an approach reduces unnecessary work and enables faster reconciliation.
A new wholesale and a company with a multi-year GDP system do not need the same engagement.
With the new organization, we build the system together with processes, space, equipment and responsibilities.
In the case of existing wholesale, we first look for a gap according to the current regulatory framework.
Based on the initial assessment, ConsultHQ can define priorities, necessary changes to documentation, training and internal verification before the CInMED inspection.
The goal is that the wholesaler can prove how it preserves the quality and integrity of the drug throughout the entire distribution process.
An initial assessment helps us define scope and next steps based on your actual business.
Request an initial assessment